AR043405A1 - SPECIFIC HUMAN ANTIBODIES FOR INTERLEUQUINE 15 (IL-15) - Google Patents

SPECIFIC HUMAN ANTIBODIES FOR INTERLEUQUINE 15 (IL-15)

Info

Publication number
AR043405A1
AR043405A1 ARP040100605A AR043405A1 AR 043405 A1 AR043405 A1 AR 043405A1 AR P040100605 A ARP040100605 A AR P040100605A AR 043405 A1 AR043405 A1 AR 043405A1
Authority
AR
Argentina
Prior art keywords
human
antibodies
homologous
human antibodies
disclosed
Prior art date
Application number
Other languages
Spanish (es)
Original Assignee
Genmab As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/374,932 external-priority patent/US7329405B2/en
Priority claimed from US10/379,741 external-priority patent/US7247304B2/en
Application filed by Genmab As filed Critical Genmab As
Publication of AR043405A1 publication Critical patent/AR043405A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se revelan anticuerpos monoclonales humanos aislados que se unen especialmente a la IL-15 (por ejemplo la IL-15 humana), y composiciones y moléculas relacionadas basadas en anticuerpos. Los anticuerpos humanos se pueden producir en un transfectoma o en un animal transgénico no humano, por ejemplo un ratón transgénico, capaz de producir isotipos múltiples de anticuerpos monoclonales humanos al someterse a un cambio de isotipo y recombinación V-D-J: También se revelan composiciones farmacéuticas que comprenden anticuerpos humanos, animales transgénicos no humanos, e hibridomas que producen los anticuerpos humanos, y métodos terapéuticos y de diagnóstico para utilizar los anticuerpos humanos. Reivindicación 1: Un anticuerpo monoclonal humano aislado que se une especialmente a la IL-15 humana, que comprende al menos una secuencia de CDR seleccionada del grupo formado por: (i) SEC ID Nos: 5, 6, 7, 8, 9, y 10; (ii) secuencias que son al menos 90% homólogas, preferentemente al menos 95% homólogas, y más preferentemente al menos 98%, o al menos 99% homólogas a las secuencias definidas en (i); y (iii) fragmentos de las secuencias definidas en (i) o (ii), que retienen la capacidad de unirse específicamente a la IL-15 humana.Isolated human monoclonal antibodies that bind especially to IL-15 (for example human IL-15), and related antibody-based compositions and molecules are disclosed. Human antibodies can be produced in a transfectome or in a non-human transgenic animal, for example a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing a change of isotype and recombination VDJ: Pharmaceutical compositions are also disclosed comprising human antibodies, non-human transgenic animals, and hybridomas that produce human antibodies, and therapeutic and diagnostic methods for using human antibodies. Claim 1: An isolated human monoclonal antibody that binds especially to human IL-15, comprising at least one CDR sequence selected from the group consisting of: (i) SEQ ID Nos: 5, 6, 7, 8, 9, and 10; (ii) sequences that are at least 90% homologous, preferably at least 95% homologous, and more preferably at least 98%, or at least 99% homologous to the sequences defined in (i); and (iii) fragments of the sequences defined in (i) or (ii), which retain the ability to specifically bind human IL-15.

ARP040100605 2003-02-26 2004-02-26 SPECIFIC HUMAN ANTIBODIES FOR INTERLEUQUINE 15 (IL-15) AR043405A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/374,932 US7329405B2 (en) 2001-08-23 2003-02-26 Human antibodies specific for interleukin 15 (IL-15)
US10/379,741 US7247304B2 (en) 2001-08-23 2003-03-05 Methods of treating using anti-IL-15 antibodies

Publications (1)

Publication Number Publication Date
AR043405A1 true AR043405A1 (en) 2005-07-27

Family

ID=36770634

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040100605 AR043405A1 (en) 2003-02-26 2004-02-26 SPECIFIC HUMAN ANTIBODIES FOR INTERLEUQUINE 15 (IL-15)

Country Status (6)

Country Link
JP (1) JP4892335B2 (en)
CN (1) CN1780856A (en)
AR (1) AR043405A1 (en)
EA (1) EA015897B1 (en)
RS (1) RS20050724A (en)
ZA (1) ZA200506724B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8492118B2 (en) 2007-05-11 2013-07-23 Altor Bioscience Corporation Fusion molecules and IL-15 variants
EP4385570A2 (en) 2010-09-21 2024-06-19 Altor BioScience, LLC Multimeric il-15 soluble fusion molecules and methods of making and using same
US11053299B2 (en) 2010-09-21 2021-07-06 Immunity Bio, Inc. Superkine
CN102250243B (en) * 2011-07-01 2013-08-28 华绍炳 Antibody to interleukins-15
EP3912637A1 (en) 2014-06-30 2021-11-24 Altor BioScience Corporation Il-15-based molecules and methods of use thereof
EP2963057A1 (en) * 2014-07-02 2016-01-06 Calypso Biotech SA Antibodies to IL-15
JP2019521981A (en) * 2016-06-15 2019-08-08 アムジエン・インコーポレーテツド Methods and compositions for treating celiac disease, non-celiac gluten hypersensitivity and refractory celiac disease
CA3041310C (en) 2016-10-21 2023-09-05 Altor Bioscience Corporation Multimeric il-15-based molecules
IL267113B1 (en) * 2016-12-21 2024-05-01 Cephalon Llc Antibodies that specifically bind to human il-15 and uses thereof
CN114786479B (en) * 2019-12-25 2023-12-15 江苏集萃药康生物科技股份有限公司 IL-15 humanized mouse model and application thereof
CN114377133A (en) * 2022-01-20 2022-04-22 山东大学 Targeting renal CD8+Application of TRM formation and activation in glomerular injury
CN115362984B (en) * 2022-07-07 2024-01-16 成都中医药大学 Construction method of mouse autoimmune thyroiditis model

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795966A (en) * 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
GB9814892D0 (en) * 1998-07-10 1998-09-09 Kennedy Rheumatology Inst Treatment of celiac disease
WO2001002003A1 (en) * 1999-07-06 2001-01-11 Bulfone Paus Silvia Method of treating psoriasis with il-15 antagonist
EA014802B1 (en) * 2001-08-23 2011-02-28 Генмаб А/С HUMAN ANTIBODIES SPECIFIC FOR INTERLEUKIN 15 (IL-15)\ (VARIANTS), A METHOD OF PRODUCING THEREOF, AN IMMUNOCONJUGATE BASED THEREON, A TRANSFECTOMA, A HYBRIDOMA, A TRANSGENIC ANIMAL, AN EXPRESSION VECTOR (VARIANTS) AND NUCLEIC ACID FOR PRODUCING THEREOF, A METHOD OF TREATMENT (VARIANTS) AND DIAGNOSING AN IL-15 MEDIATED DISEASE, A METHOD OF INHIBITING IL-15 INDUCED TNF-α, AND A METHOD OF INHIBITING INDUCED IL-15 CELL PROLIFERATION.

Also Published As

Publication number Publication date
CN1780856A (en) 2006-05-31
RS20050724A (en) 2007-11-15
EA200501362A1 (en) 2006-02-24
ZA200506724B (en) 2007-03-28
JP4892335B2 (en) 2012-03-07
EA015897B1 (en) 2011-12-30
JP2007528348A (en) 2007-10-11

Similar Documents

Publication Publication Date Title
LTC3284753I2 (en)
DK1425389T3 (en) Interleukin-15- (IL-15) -specific human antibodies
DE60031279D1 (en) HUMAN MONOCLONAL ANTIBODIES AGAINST PROSTATE SPECIFIC MEMBRANEANT
TW200500378A (en) Human antibodies specific for interleukin 15 (IL-15)
BRPI0210405B8 (en) human monoclonal antibody, bispecific molecule, in vitro method to inhibit the growth of a cell expressing egfr, to induce cytolysis of a cell expressing egfr, and to detect the presence of egfr antigen or a cell expressing egfr in a sample, e, vector of expression
ATE531731T1 (en) HUMAN MONOCLONAL ANTIBODIES AGAINST THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR)
EA200500835A1 (en) HUMAN MONOCLONAL ANTIBODIES AGAINST CD25
NO20053417L (en) Human monoclonal antibodies to interleukin 8 (IL-8)
ATE384744T1 (en) HUMAN ANTIBODIES AGAINST HER2/NEW
AR047372A1 (en) ANTIBODIES AGAINST MADCAM
ATE553131T1 (en) HUMAN MONOCLONAL ANTIBODIES AGAINST DENDRITIC CELLS
AR043405A1 (en) SPECIFIC HUMAN ANTIBODIES FOR INTERLEUQUINE 15 (IL-15)
TH79238A (en) Human antibodies specific to interleukin 15 (IL-15).
TH79238B (en) Human antibodies specific to interleukin 15 (IL-15).

Legal Events

Date Code Title Description
FB Suspension of granting procedure
FA Abandonment or withdrawal
FC Refusal